Abhishek Singh

Abhishek Singh

Auto-generated profile, based on publicly available information

Abhishek Singh

National Forensic Sciences University, Ponda, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Global Ecology and Conservation
Verified
Journal Article
Open access
TMTanoy Mukherjee
Tanoy Mukherjee
ICIshita Chongder
Ishita Chongder
SGShankhamala Ghosh
Shankhamala Ghosh
ADAkash Dutta
Akash Dutta
ASAbhishek Singh
Abhishek Singh
KCKailash Chandra
Kailash Chandra

17 September 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASAbhishek Singh
Abhishek Singh
MTMukesh Thakur
Mukesh Thakur
SSSujeet Kumar Singh
Sujeet Kumar Singh
LSLalit Kumar Sharma
Lalit Kumar Sharma
KCKailash Chandra
Kailash Chandra
YPEL3 that induces cellular senescence in both normal and tumour cells of humans may show altered expression under the influence of incidental mutations. In this study, we proposed the first structure of Native YPEL3 protein and its five possible deleterious mutants—V40M, C61Y, G98R, G108S, and A131T and predicted their deleterious effects to alter stability, flexibility and conformational changes in the protein. The MD simulation (RMSD, RMSF, Rg, h-bond and SASA) analysis revealed that the variants V40M, G98R and G108S increased the flexibility in protein, and variant V40M imparted more compactness to the protein.. In general, variants attributed changes in the native conformation and structure of the YPEL3 protein which might affect the native function of cellular senescence. The study provides opportunities for health professionals and practitioners in formulating précised medicines to effectively cure various cancers. We propose in-vitro or in-vivo studies should consider these reported nsSNPs while examining any malfunction in the YPEL3 protein.

1 June 2021 in Forensic Science International
Verified
Journal Article
Closed access
PPPrajnashree Priyambada
Prajnashree Priyambada
GJGul Jabin
Gul Jabin
ASAbhishek Singh
Abhishek Singh
AGAvijit Ghosh
Avijit Ghosh
SSSujeet Kumar Singh
Sujeet Kumar Singh
MTMukesh Thakur
Mukesh Thakur

3 July 2020 in International journal of legal medicine
Verified
Journal Article
Closed access
PDF file
ASAbhishek Singh
Abhishek Singh
PPPrajnashree Priyambada
Prajnashree Priyambada
GJGul Jabin
Gul Jabin
SSSujeet Kumar Singh
Sujeet Kumar Singh
BJBheem Dutt Joshi
Bheem Dutt Joshi
MTMukesh Thakur
Mukesh Thakur

16 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAbhishek Singh
Abhishek Singh
MTMukesh Thakur
Mukesh Thakur
LSLalit Kumar Sharma
Lalit Kumar Sharma
KCKailash Chandra
Kailash Chandra
COVID-19 pandemic has resulted so far 14,395,16 confirmed cases with 85,711 deaths from the 212 countries, or territories. Due to multifacet issues and challenges in implementation of the safety & preventive measures, inconsistent coordination between societies-governments and most importanly lack of specific vaccine to SARS-CoV-2, the spread of Wuhan originated virus is still uprising after taking a heavy toll on human life. In the present study, we mapped several immunogenic epitopes (B-cell, T-cell, and IFN-gamma) over the entire structural proteins of SARS-CoV-2 and by applying various computational and immunoinformatics approaches, we designed a multi-epitope peptide based vaccine that predicted high immunogenic response in the largest proportion of world’s human population. To ensure high expression of the recombinant vaccine in E. coli , codon optimization and in-silico cloning were also carried out. The designed vaccine with high molecular affinity to TLR3 and TLR4, was found capable to initiate effective innate and adaptive immune response. The immune simulation also suggested uprising high levels of both B-cell and T-cell mediated immunity which on subsequent exposure cleared antigen from the system. The proposed vaccine found promising by yielding desired results and hence, should be tested by practical experimentations for its functioning and efficacy to neutralize SARS-CoV-2.

19 November 2019 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
ASAbhishek Singh
Abhishek Singh
MTMukesh Thakur
Mukesh Thakur
VSVivek Sahajpal
Vivek Sahajpal
SSSujeet K. Singh
Sujeet K. Singh
KCKailash Chandra
Kailash Chandra
ABAusma Bernot
Ausma Bernot
Objectives: The human specific commercially available STRs system are often not tested in non human primates for their cross applicability. The aim of this study is to test Cross-species validation of two commercially available human specific STR kits i.e. SureID®21G and SureID®23comp (Health Gene Technologies) for their positive application in Chimpanzee (Pan troglodytes).Result: In SureID®21G, 19 loci amplified and while 20 loci amplified in SureID®23comp. All the amplified loci in both STR kits were found polymorphic and the locus Amelogenin showed differential banding patterns between male and female revealing their known gender. The present study validates the applicability of these human specific STR kits in Chimpanzee that can be used in forensics analysis, paternity testing and population genetic studies.